Has Kim Nagel received payments from drug or device companies?

Yes. Drug and device makers reported $4,780 in general payments to Kim Nagel across 202 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kim Nagel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kim Nagel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kim Nagel

Psychiatry · Meridian, MSNPI 1235373663

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alkermes, Inc. at 34.8% of the total.

$4,780in general payments, 2019–2025

Across 202 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$2K
Johnson & Johnson$1K
Otsuka America Pharmaceutical, Inc.$693
Neurocrine Biosciences, Inc.$336
Vanda Pharmaceuticals Inc.$316
Lundbeck LLC$204
plus $555 from 8 others

What the payments were for

Food & beverage$4,780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	65	$1,662
Johnson & Johnson	50	$1,015
Otsuka America Pharmaceutical, Inc.	25	$693
Neurocrine Biosciences, Inc.	10	$336
Vanda Pharmaceuticals Inc.	13	$316
Lundbeck LLC	10	$204
E.r. Squibb & Sons, L.L.C.	9	$193
Teva Pharmaceuticals USA, Inc.	10	$190
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$84
AbbVie	2	$28
Avanir Pharmaceuticals, Inc.	1	$20
Greenwich Biosciences, Inc.	1	$15
AstraZeneca	1	$13
GSK	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,780 in reported general payments places this provider in the 85th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clozapine	84	$4,047
Divalproex Sodium	15	$436
Olanzapine	19	$324
Citalopram HbrCitalopram Hydrobromide	11	$24

Paid to pharmacies, not to this prescriber.

Other psychiatry in Meridian

Terry JordanMeridian$5K
Ruben CruzMeridian$4K
William TouchstoneMeridian$4K
Mary LarkinMeridian$2K
Patricia DudleyMeridian$2K
Maxie GordonClinton$1.3M
Kurt BuechlerRidgeland$1.1M
Chasity TorrenceWhitfield$834K
Jon JacksonJackson$834K
John NortonJackson$173K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →